Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…their proven efficacy, there remains a gap in the initiation of Sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus patients with evidence of coronary …
…therapy with SGLT2i and GLP-1 RA relative to those who received SGLT2i monotherapy was significantly lower in patients with HF and T2D…
…particularly relevant for GLP-1 receptor agonists. For example, semaglutide has demonstrated dose-dependent effects on glycemic control and…
…quency (episodes per person or per unit time, as reported). (4) Insulin dosage: we extracted total daily dose (TDD) and weight-normaliz…
…le patients will be randomised in a 1:1 ratio to receive either dapagliflozin (10 mg once daily) or a matching placebo for a duration of 1 ye…
…ient, with ICERs generally below willingness-to-pay thresholds. Dapagliflozin was cost saving in type 2 diabetes (T2D) in the United Kingdom …
…e to prevent the progression of chronic kidney disease, such as sodium-glucose cotransporter 2 inhibitors.Future research We recommend that our model should be validated…
…hese neurohumoral pathways, most notably with beta-blockers and ACE inhibitors. At present, HF is defined as ‘a clinical syndrome with signs a…
…ristics and outcomes of patients with T2D and CKD who initiated SGLT2i or GLP-1 RA in China. The results are important for understandi…
…arched. All randomised controlled clinical trials investigating Finerenone combined with SGLT2i for DKD treatment will be included. Data e…
…d significantly after intervention (−2.0% per quarter; p=0.02). Insulin prescribing rates did not change throughout the study period. T…